U.S. News ranks Houston hospital No. 1 in Texas for 14th year in a row

Topping the Charts

Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report has released its 2025 rankings of the best hospitals in Texas, and they prove that Houston is in good hands.

The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35.

U.S. News annually evaluates 581 Texas hospitals to determine which meet the publication's rigorous standards and offer the best care for patients. Hospitals are also ranked among 15 specialties, including cancer, cardiology, heart and vascular surgery, obstetrics and gynecology, orthopedics, psychiatry, rehabilitation, diabetes and endocrinology, and more.

Houston Methodist also appeared on U.S. News' prestigious list of Honor Roll hospitals, consisting of 20 medical centers that are deemed the "best of the best" hospitals in the nation. No other Texas hospitals made the list, further proving that Houston Methodist takes exceptional care of its patients.

"This is a tremendous achievement for our physicians and employees who dedicate themselves every day to our patients," said Marc Boom, M.D., president and CEO of Houston Methodist, in a press release. "We take pride in these national recognitions but more importantly, these accolades reflect our unparalleled commitment to keeping our patients at the center of everything we do."

Houston Methodist earned several top-20 rankings across 11 of the 15 total specialties nationwide. It also earned national recognition for having the 7th best gastroenterology/GI surgery program, the 8th best pulmonology and lung surgery programs, and the 10th best diabetes and endocrinology programs in the country.

Elsewhere in Houston, The University of Texas MD Anderson Cancer Center ranked as the No. 1 best cancer hospital in the nation for the 11th year in a row.

"We are honored to again be ranked as the nation’s top hospital for cancer care – a recognition that reaffirms our commitment to our shared mission to end cancer," said MD Anderson president Peter WT Pisters, M.D., in a release. "We are grateful to every one of our teammates, trainees, students, donors, volunteers, advocates and patients, whose unwavering dedication make it possible for MD Anderson to deliver outstanding patient care."

Other top-performing Houston-area hospitals that ranked among the best in Texas include:

  • No. 4 – Baylor St. Luke's Medical Center
  • No. 5 – Memorial Hermann Greater Heights Hospital
  • No. 6 – Memorial Hermann Hospital
  • No. 8 – Houston Methodist Sugar Land Hospital
  • No. 9 – Houston Methodist Willowbrook Hospital
  • No. 12 – Houston Methodist The Woodlands Hospital
  • No. 13 – Memorial Hermann Memorial City Medical Center (tied with Baylor Scott and White All Saints Medical Center - Fort Worth)
  • No. 21 – Houston Methdodist Baytown Hospital (tied with Methodist Hospital - Stone Oak in San Antonio and Texas Health Harris Methodist Hospital Fort Worth)
  • No. 25 – HCA Houston Healthcare Clear Lake in Webster (tied with St. Luke's Health - The Woodlands Hospital, Baylor Scott and White Medical Center - Round Rock-Lakeway, and Texas Health Presbyterian Hospital Plano)
  • No. 29 – University of Texas Medical Branch in Galveston (tied with Medical City Plano)
---

This article originally appeared on CultureMap.com.

From Your Site Articles
The merger that would have created the largest hospital system in Texas has been called off. Photo via memorialhermann.org

Major Texas hospital merger between Memorial Hermann and Baylor Scott & White called off

Discharged

Two Texas hospitals that were headed for union have called off their engagement plans, according to a joint statement. Dallas-based Baylor Scott and White and Houston-based Memorial Hermann announced in October that they were on track to combine forces following a letter of intent to merge and create a combined system.

The merger would have created a system with over 68 hospital campuses, 1,100 care delivery sites, almost 14,000 physicians, and serve almost 10 million patients each year, according to the October release. The more formalized agreement was expected this year.

"After months of thoughtful exploration, we have decided to discontinue talks of a merger between our two systems," the February 5 release states. "Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time."

Jim Hinton, current CEO of Baylor Scott and White, was announced to be the system's CEO. Chuck Stokes, president and CEO of Memorial Hermann, was said to serve in the proposed office of the CEO, along with Baylor Scott and White president, Pete McCanna.

"We have a tremendous amount of respect for each other and remain committed to strengthening our communities, advancing the health of Texans and transforming the delivery of care," the release continues. "We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations."

This story will be updated as more information becomes available.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

View All Listings